Introduction to Prothena

Prothena Corporation plc was established as a fully independent company in December 2012 following completion of a spin-off from Elan. Prothena (Nasdaq:PRTA) is a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion, particularly on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis, Parkinson's disease and related synucleinopathies, and novel cell adhesion targets involved in inflammatory disease and metastatic cancers.